Douglas Corley to Mass Screening
This is a "connection" page, showing publications Douglas Corley has written about Mass Screening.
Connection Strength
3.151
-
Promises and Potential Pitfalls of Shared Decision Making in Cancer Screening. Gastroenterology. 2020 03; 158(4):802-805.
Score: 0.448
-
Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis. Gastroenterology. 2019 12; 157(6):1494-1505.
Score: 0.439
-
Reducing Variation in the "Standard of Care" for Cancer Screening: Recommendations From the PROSPR Consortium. JAMA. 2016 May 17; 315(19):2067-8.
Score: 0.350
-
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 07 10; 371(2):186.
Score: 0.308
-
Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. J Natl Cancer Inst. 2015 Jun; 107(6):djv120.
Score: 0.163
-
COVID-19: What Should Clinicians and Scientists Do and When? Gastroenterology. 2020 Jun; 158(8):2020-2023.
Score: 0.114
-
Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019 Oct 02; 367:l5515.
Score: 0.111
-
Comparison of Universal Versus Age-Restricted Screening of Colorectal Tumors for Lynch Syndrome Using Mismatch Repair Immunohistochemistry: A Cohort Study. Ann Intern Med. 2019 07 02; 171(1):19-26.
Score: 0.108
-
Colorectal Cancer Screening Initiation After Age 50 Years in an Organized Program. Am J Prev Med. 2017 Sep; 53(3):335-344.
Score: 0.093
-
Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. Clin Gastroenterol Hepatol. 2016 10; 14(10):1445-1451.e8.
Score: 0.088
-
Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. Am J Prev Med. 2016 10; 51(4):507-12.
Score: 0.087
-
Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. Am J Prev Med. 2016 10; 51(4):e107-15.
Score: 0.087
-
Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems. Cancer Epidemiol Biomarkers Prev. 2016 Feb; 25(2):344-50.
Score: 0.086
-
Colorectal cancer deaths attributable to nonuse of screening in the United States. Ann Epidemiol. 2015 Mar; 25(3):208-213.e1.
Score: 0.079
-
Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013 Mar 05; 158(5 Pt 1):312-20.
Score: 0.070
-
Optimal Stopping Ages for Colorectal Cancer Screening. JAMA Netw Open. 2024 Dec 02; 7(12):e2451715.
Score: 0.040
-
Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death. JAMA Netw Open. 2024 Jul 01; 7(7):e2423671.
Score: 0.038
-
Population-level impact of the BMJ Rapid Recommendation for colorectal cancer screening: a microsimulation analysis. BMJ Open Gastroenterol. 2024 May 09; 11(1).
Score: 0.038
-
Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning Ten Years after a Negative Colonoscopy, among Screen-Eligible Adults 76 to 85 Years Old. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):37-45.
Score: 0.035
-
Evaluation of Harms Reporting in U.S. Cancer Screening Guidelines. Ann Intern Med. 2022 11; 175(11):1582-1590.
Score: 0.034
-
Gaps in the screening process for women diagnosed with cervical cancer in four diverse US health care settings. Cancer Med. 2023 Feb; 12(3):3705-3717.
Score: 0.034
-
Estimating Cancer Screening Sensitivity and Specificity Using Healthcare Utilization Data: Defining the Accuracy Assessment Interval. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1517-1520.
Score: 0.034
-
Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1521-1531.
Score: 0.034
-
Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology. 2002 Mar; 122(3):633-40.
Score: 0.033
-
The effect of using fecal testing after a negative sigmoidoscopy on the risk of death from colorectal cancer. J Med Screen. 2021 06; 28(2):140-147.
Score: 0.029
-
Colorectal Cancer Screening in People With and Without HIV in an Integrated Health Care Setting. . 2019 07 01; 81(3):284-291.
Score: 0.027
-
Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev. 2018 02; 27(2):158-164.
Score: 0.024
-
Impact of adenoma detection on the benefit of faecal testing vs. colonoscopy for colorectal cancer. Int J Cancer. 2017 12 01; 141(11):2359-2367.
Score: 0.024
-
Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test. JAMA. 2017 08 01; 318(5):483.
Score: 0.024
-
Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. Dig Dis Sci. 2017 03; 62(3):678-688.
Score: 0.023
-
Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly. Am J Prev Med. 2016 09; 51(3):e67-75.
Score: 0.022
-
Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer. 2015 Jul 01; 121(13):2281-5.
Score: 0.020
-
A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology. 2004 Jul; 127(1):310-30.
Score: 0.010